Fennec Pharmaceuticals Reports Second Quarter 2024 Financial …

Aug 13, 2024 · RESEARCH TRIANGLE PARK, N.C., Aug. 13, 2024 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical …

CouponFollow Extension

$7
OFF

Fennec Pharmaceuticals Reports Second Quarter 2024 Financial …

1 week from now

Aug 13, 2024 · Story continues. Financial Results for the Second Quarter 2024. Net Sales – The Company recorded net product sales of $7.3 million for the three-month period ended June 30, …

yahoo.com

118%
OFF

Fennec Pharmaceuticals Second Quarter 2024 Earnings: Misses …

1 week from now

Aug 15, 2024 · Fennec Pharmaceuticals (NASDAQ:FENC) Second Quarter 2024 ResultsKey Financial Results. Revenue: US$7.26m (up 118% from 2Q 2023). Net loss: US$5.55m (loss …

yahoo.com

$6
OFF

Fennec Pharmaceuticals Reports Third Quarter 2024 Financial …

1 week from now

Sep 30, 2024 · Fennec Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update. ... Expenses – G&A expenses were $6.1 million compared to $3.8 …

fennecpharma.com

$7
OFF

Fennec Pharmaceuticals Reports Second Quarter 2024 Financial …

1 week from now

Aug 13, 2024 · Financial Results for the Second Quarter 2024 Net Sales – The Company recorded net product sales of $7.3 million for the three-month period ended June 30, 2024, …

morningstar.com

$7
OFF

Fennec Pharmaceuticals Reports Q3 2024 Financial Results

1 week from now

Nov 9, 2024 · In its latest earnings report, Fennec Pharmaceuticals reported net product sales of $7.0 million for the third quarter of 2024, highlighting increased momentum in the adolescent …

businessinsider.com

$7
OFF

Fennec Pharmaceuticals Reports Strong Q3 Results

1 week from now

4 days ago · Nov. 12, 2024, 06:11 PM. Fennec Pharmaceuticals (TSE:FRX) has released an update. Fennec Pharmaceuticals reported solid third-quarter financial results with $7.0 million …

businessinsider.com

$7
OFF

Fennec Pharmaceuticals Reports Strong Q3 Results - Nasdaq

1 week from now

4 days ago · Fennec Pharmaceuticals reported solid third-quarter financial results with $7.0 million in net product sales, bolstered by strategic investments in the Adolescent and Young Adult …

nasdaq.com

$803
OFF

Xenon Reports Q3 2024 Financial Results And Business Update

1 week from now

5 days ago · Third Quarter Financial Results. Cash and cash equivalents and marketable securities were $803.3 million as of September 30, 2024, compared to $930.9 million as of …

xenon-pharma.com

$8
OFF

Marinus Pharmaceuticals Provides Business Update And Reports …

1 week from now

5 days ago · Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results. ZTALMY ® (ganaxolone) Q3 2024 net product revenue of $8.5 million …

morningstar.com

FAQs about Fennec Pharmaceuticals Reports Second Quarter 2024 Financial … Coupon?

How did fennec pharmaceuticals perform in Q3 2024?

In its latest earnings report, Fennec Pharmaceuticals reported net product sales of $7.0 million for the third quarter of 2024, highlighting increased momentum in the adolescent and young adult segment, along with successful reimbursement efforts. The company also announced strategic executive appointments to bolster its leadership team. ...

Is fennec pharmaceuticals participating in upcoming conferences?

Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX) announced that the Company will be participating in upcoming conferences. The management team will also host one-on-one meetings. ...

What information did fennec pharmaceuticals present to its investors?

Here is a breakdown of the information Fennec Pharmaceuticals presented to its investors. Fennec Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing PEDMARK, a treatment to reduce the risk of chemotherapy-induced ototoxicity in pediatric patients, operating within the pharmaceutical industry. ...

Does fennec have a strong cash position in 2026?

Despite the increase in operating expenses to $12.2 million, Fennec has maintained a strong cash position, with $40 million in cash and equivalents, expected to fund operations into 2026. The company continues to invest in awareness campaigns for PEDMARK, which has seen over 90% reimbursement in its targeted market. ...

Is fennec poised for growth in international markets?

Strategically, Fennec is poised for growth in international markets, with PEDMARQSI’s upcoming launch in Europe set to generate additional revenue in the coming years. Additionally, the completion of a clinical trial in Japan could pave the way for PEDMARK’s registration in the region. ...

What is fennec doing with pedmarqsi?

The company continues to invest in awareness campaigns for PEDMARK, which has seen over 90% reimbursement in its targeted market. Strategically, Fennec is poised for growth in international markets, with PEDMARQSI’s upcoming launch in Europe set to generate additional revenue in the coming years. ...